Metraipolis › archive › dc_7ab8a72b4e81

4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status — Europe PMC PMID:41547841

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41547841
DOI: 10.1186/s12959-[numero omesso]-x
License (as archived): solo-consultazione
Archived: 2026-11-06T17:47:03.050Z
SHA-256 of the archived text: 5ddd135e58c27a4da09b3ee52a201ecda869f8934ac72131b02dd9b3dcf5ac5f
Stable URL of this page: https://metraipolis.com/documento/dc_7ab8a72b4e81

How to cite

4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status — Europe PMC PMID:41547841 — Europe PMC (en), https://europepmc.org/article/MED/41547841 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7ab8a72b4e81 (Metraipolis archive dc_7ab8a72b4e81, sha256 5ddd135e58c27a4da09b3ee52a201ecda869f8934ac72131b02dd9b3dcf5ac5f)

BibTeX

@misc{dc7ab8a72b4e81,
  title = {4G/5G polymorphism and plasma levels of plasminogen activator inhibitor-1 in essential thrombocythemia patients with driver mutational status — Europe PMC PMID:41547841},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41547841},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7ab8a72b4e81; sha256 5ddd135e58c27a4da09b3ee52a201ecda869f8934ac72131b02dd9b3dcf5ac5f},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41547841. Agents can read the archived copy with the MCP tool read_document.